Omega Fund Management disclosed a buy of 187,500 shares of Bicara Therapeutics (NASDAQ:BCAX) in a May 15, 2026, SEC filing, with the estimated transaction value at $3.23 million based on quarterly average pricing. According to an SEC filing dated May 15, 2026, Omega Fund Management bought 187,500 additional shares of Bicara Therapeutics, with an estimated transaction value of $3.23 million based o...
Omega Fund Management disclosed a buy of 187,500 shares of Bicara Therapeutics (NASDAQ:BCAX) in a May 15, 2026, SEC filing, with the estimated transaction value at $3.23 million based on quarterly average pricing. According to an SEC filing dated May 15, 2026, Omega Fund Management bought 187,500 additional shares of Bicara Therapeutics, with an estimated transaction value of $3.23 million based on the average closing price from January through March 2026. The quarter-end value of the BCAX position increased by $10.48 million, a figure that includes both the share addition and price appreciation during the period. Bicara Therapeutics is a clinical-stage biotechnology company specializing in the development of innovative bifunctional antibody therapies for solid tumor cancers. The company’s strategy centers on advancing its lead program, ficerafusp alfa, through clinical development to address significant unmet needs in oncology. Continue reading
design master/iStock via Getty Images Nova Ltd. ( NVMI ) was one of those situations where the share price was quite expensive, but fundamental momentum was too strong for me to rate it a hold. Now, after the share price ran up almost 100% and the latest earnings, I believe it is worth revisiting the old thesis. In my last thesis, I was writing about the company being one of the strongest semicond...
design master/iStock via Getty Images Nova Ltd. ( NVMI ) was one of those situations where the share price was quite expensive, but fundamental momentum was too strong for me to rate it a hold. Now, after the share price ran up almost 100% and the latest earnings, I believe it is worth revisiting the old thesis. In my last thesis, I was writing about the company being one of the strongest semiconductor metrology players, which directly stands on AI, GAA, HBM, and advanced packaging cycles. The additional benefits to the thesis were also a strong balance sheet and high margins. I know that some will recall that I said that valuation was the problem and that the stock was overvalued, but as always, it's not about cheapness but whether the company can reach its premium. Now Q1 2026 results proved my thesis, and I am maintaining my rating. After my first article, the market pushed the stock even higher, making its valuation now even more expensive. The most important, in my opinion, though, is that Nova started showing first results that justified that premium. Q2 2025 was really the first proof; revenue then reached $220 million, grew 40% YoY, and GAAP EPS reached $2.14, compared to $1.41 a year ago. That was not a small beat. I consider this earnings acceleration, which for my strategy is very important. Nova still grows revenue and maintains profitability above the guidance. So, my last problem about valuation did not go anywhere, but it is not breaking the thesis either. Earnings Momentum Given that stocks like this are rarely cheap, it is worth looking at revenue growth and earnings strength and looking for signs of potential slowdown. Q1 2026, in this case, was a very good quarter. Revenue reached $235.3 million, which QoQ is 6%, and if we take YoY, a 10% increase. Net income was $69.3 million, and EPS reached $2.04; those are completely solid numbers. Gross margin is what I like about the company, and it stayed high at 57.7%, which is also good because we do not ...
On May 15, 2026, Omega Fund Management disclosed in an SEC filing that it sold 411,968 shares of Alumis (NASDAQ:ALMS) , with the estimated transaction value at $10.3 million based on quarterly average pricing. According to its SEC filing dated May 15, 2026, Omega Fund Management reduced its position in Alumis by 411,968 shares during the first quarter. The estimated transaction value, based on the...
On May 15, 2026, Omega Fund Management disclosed in an SEC filing that it sold 411,968 shares of Alumis (NASDAQ:ALMS) , with the estimated transaction value at $10.3 million based on quarterly average pricing. According to its SEC filing dated May 15, 2026, Omega Fund Management reduced its position in Alumis by 411,968 shares during the first quarter. The estimated transaction value, based on the period’s average closing price, was $10.3 million. The fund’s stake at quarter-end stood at 241,255 shares, with the position’s value decreasing by $1.06 million compared to the prior quarter, a figure reflecting both sale activity and market price movement. Alumis is positioned in the biotechnology sector, leveraging expertise in allosteric TYK2 inhibition to address complex immune-mediated conditions. Its research and development pipeline targets significant opportunities in autoimmune and neuroinflammatory disease treatment. Continue reading
Google’s YouTube and Snap Inc. reached agreements to settle the first lawsuit headed to trial over claims that addiction to top social media platforms has disrupted learning and pushed public schools to spend massive sums fighting a mental health crisis, according to court filings. TikTok and Meta Platforms Inc. were also sued by the rural Kentucky school district that brought the case, which is s...
Google’s YouTube and Snap Inc. reached agreements to settle the first lawsuit headed to trial over claims that addiction to top social media platforms has disrupted learning and pushed public schools to spend massive sums fighting a mental health crisis, according to court filings. TikTok and Meta Platforms Inc. were also sued by the rural Kentucky school district that brought the case, which is set to go to trial on June 12 in federal court in Oakland, California. The trial will serve as a test case for more than 1,200 similar lawsuits nationwide in which school districts allege that the biggest social media companies have harmed students so badly that it’s undermining the education system. The spate of lawsuits could open the tech companies to a “collective theoretical liability of almost $400 billion,” according to an estimate from Bloomberg Intelligence. The terms of the settlements weren’t disclosed in Friday’s filings. “For more than a decade, we’ve built YouTube responsibly — working with teachers, administrators, and parents’ groups to give students safer, more helpful experiences online,” a YouTube spokesperson said in a statement. “This matter has been amicably resolved and our focus remains on building age-appropriate products and parental controls that deliver on that promise.” The settlements are the latest in what has been a busy year for child safety-related litigation . TikTok and Snap previously settled a first-of-its-kind personal injury suit over social media addiction shortly before it went to trial in Los Angeles earlier this year. Meta and Google did not settle, and a jury found them liable for harming a 20-year-old woman with products designed to be addictive. Meta also lost a separate case in New Mexico alleging the company failed to protect children from online predators; jurors assessed a penalty of $375 million on Meta. The four social media companies face thousands of additional lawsuits from school districts, state attorneys general and ...
Key Takeaways Optiver US LLC's substantial $6 billion increase in Amazon (AMZN) exposure highlights a strong institutional conviction in the tech giant's long-term growth, particularly in its high-margin segments. increase in Amazon (AMZN) exposure highlights a strong institutional conviction in the tech giant's long-term growth, particularly in its high-margin segments. Amazon's Q1 2026 results d...
Key Takeaways Optiver US LLC's substantial $6 billion increase in Amazon (AMZN) exposure highlights a strong institutional conviction in the tech giant's long-term growth, particularly in its high-margin segments. increase in Amazon (AMZN) exposure highlights a strong institutional conviction in the tech giant's long-term growth, particularly in its high-margin segments. Amazon's Q1 2026 results demonstrated robust top-line growth of 17% and a record 13.1% operating margin, propelled by AWS's 28% expansion and continued advertising strength. results demonstrated robust top-line growth of and a record operating margin, propelled by expansion and continued advertising strength. Despite heavy $200 billion capital expenditures for AI infrastructure impacting free cash flow, Wall Street analysts maintain a "Buy" consensus with price targets suggesting significant upside from current levels. Why is Optiver Betting Big on Amazon (AMZN) Now? Optiver US LLC, a prominent high-frequency trading and market-making firm known for its sophisticated algorithmic strategies, has dramatically increased its exposure to Amazon (AMZN), adding over $6 billion in new capital to make it a top holding. This isn't a casual portfolio adjustment; it signals a deep-seated conviction in Amazon's future trajectory, especially given Optiver's strategic focus on technological leverage and expanding U.S. market-making capabilities. Their move suggests a belief that Amazon's underlying fundamentals and growth catalysts are compelling enough to warrant such a substantial investment. The timing of Optiver's increased stake coincides with a dynamic period for Amazon shares. As of May 15, 2026, AMZN trades at $264.14, reflecting a slight daily dip of -1.15% from its previous close of $267.22. This follows a remarkable run where the stock surged 27% in the last month, positioning it as the best-performing "Magnificent Seven" stock year-to-date. This recent rebound comes after a challenging period earlier i...
PM Images/DigitalVision via Getty Images Introduction The Dividend Champions list is a monthly compilation of companies that have consistently increased their annual dividend payouts. However, since this list is only produced once per month, the data in it can quickly get out of date. Furthermore, with around 700 companies on the list, the sheer amount of data can quickly become overwhelming. In t...
PM Images/DigitalVision via Getty Images Introduction The Dividend Champions list is a monthly compilation of companies that have consistently increased their annual dividend payouts. However, since this list is only produced once per month, the data in it can quickly get out of date. Furthermore, with around 700 companies on the list, the sheer amount of data can quickly become overwhelming. In this weekly series, I highlight recent and upcoming dividend-related activity for dividend stocks on the Dividend Champions list. In the data presented below, Yield is forward annualized, and Years reflects the up-to-date streak, including dividends declared since the last edition of the Dividend Champions list. Dividend Changes In the past week, the following companies declared dividends that changed from their previous payouts. Increases: Company Symbol Ex-Div Pay Old Rate New Rate Increase Yield Years Muncy Columbia Financial Corporation ( CCFN ) 5/26 6/11 0.153333 0.155 1.09% 2.38% 29 Curtiss-Wright Corporation ( CW ) 6/15 7/6 0.24 0.26 8.33% 0.15% 10 Farmers & Merchants Bancorp ( FMCB ) 6/12 7/1 5.1 5.35 4.90% 1.59% 63 Hyster-Yale Materials Handling, Inc. ( HY ) 6/1 6/16 0.36 0.365 1.39% 4.09% 15 NACCO Industries, Inc. ( NC ) 6/1 6/15 0.2525 0.2625 3.96% 2.13% 41 Penske Automotive Group, Inc. ( PAG ) 5/26 6/3 1.4 1.42 1.43% 3.50% 6 RLI Corp. ( RLI ) 5/29 6/12 0.16 0.18 12.50% 1.42% 51 Click to enlarge Decreases: None Last Chance To Buy These dividend growth stocks have ex-dividend dates approaching. The following tables indicate the last day you can buy these stocks in order to be eligible for the upcoming dividend. Tables are sorted alphabetically by symbol. Monday, May 18 (Ex-Div 5/19) Company Symbol Pay Date Payout Price Yield Years Avista Corporation ( AVA ) 6/12 0.4925 40.41 4.88% 24 BWX Technologies, Inc. ( BWXT ) 6/5 0.27 204.72 0.53% 11 Chevron Corporation ( CVX ) 6/10 1.78 191.10 3.73% 39 Fresh Del Monte Produce Inc. ( FDP ) 6/11 0.3 32.49 3.69% 6 Innospec Inc....
Mohammad Baqer Saad Dawood al-Saadi appeared in US federal court to face six terrorism-related charges The US justice department has arrested and charged an Iraqi national accused of involvement in nearly 20 alleged terror attacks and attempted attacks across the US and Europe . The wave of violence attributed to Mohammad Baqer Saad Dawood al-Saadi has caused huge concern in many European countrie...
Mohammad Baqer Saad Dawood al-Saadi appeared in US federal court to face six terrorism-related charges The US justice department has arrested and charged an Iraqi national accused of involvement in nearly 20 alleged terror attacks and attempted attacks across the US and Europe . The wave of violence attributed to Mohammad Baqer Saad Dawood al-Saadi has caused huge concern in many European countries but especially the UK, where Jewish community centres, charities, synagogues and other sites have been targeted in recent weeks. Continue reading...
Omega Fund Management cut its stake in Kestra Medical Technologies (NASDAQ:KMTS) , selling 351,442 shares in the first quarter for an estimated $8.28 million based on quarterly average pricing, according to a May 15, 2026, SEC filing. According to an SEC filing published May 15, 2026, Omega Fund Management decreased its position in Kestra Medical Technologies, Ltd. by 351,442 shares during the fir...
Omega Fund Management cut its stake in Kestra Medical Technologies (NASDAQ:KMTS) , selling 351,442 shares in the first quarter for an estimated $8.28 million based on quarterly average pricing, according to a May 15, 2026, SEC filing. According to an SEC filing published May 15, 2026, Omega Fund Management decreased its position in Kestra Medical Technologies, Ltd. by 351,442 shares during the first quarter. The estimated transaction value was $8.28 million, calculated using the average unadjusted closing price for the quarter. The fund’s quarter-end holding was 1,022,149 shares, with a reported value of $20.37 million. Kestra Medical Technologies, Ltd. is a healthcare technology company specializing in advanced wearable devices and digital platforms for cardiac patient management. The company leverages intelligent, connected solutions to support both patients and providers, aiming to enhance clinical outcomes in cardiovascular disease. With a focus on innovation and integration, Kestra develops next-generation cardiac monitoring and intervention solutions. Continue reading